Our Vision & Expertise
Advancing Immunodiagnostics Through Scientific Innovation
IMIWN is a division of J R Biomedical Limited, and our vision is to advance the landscape of critical care and inflammatory disease management through pioneering immunological diagnostics. We are a UK-based biotechnology company driven by a commitment to translating cutting-edge science into accessible, high-impact diagnostic solutions.
Our Core Expertise
Our strength lies in our expertise in development, and validation of in-vitro diagnostics, particularly within the complex realm of systemic inflammation and immune dysregulation. Our scientific team comprises experts in immunology, clinical diagnostics, and assay development, collectively dedicated to addressing unmet needs in sepsis and inflammation.
We focus on biomarkers that offer;
- Mechanistic Insight: Providing understanding into fundamental immunological processes
- Rapid Kinetics: Enabling timely intervention and dynamic monitoring
- Clinical Utility: Translating into actionable information for patient care and research
The IMIWN sTLR2 RAPID Test embodies this commitment, representing years of dedicated research and development into rapid tests for soluble Toll-like Receptor 2 – a key mediator of the innate immune response. We believe that by providing immunologists and clinicians with precise tools to assess immune status, we can potentially improve outcomes in critical conditions like sepsis and other severe inflammatory states.
Our innovative technology is supported by a defined roadmap for scalability and positioned for growth through strategic partnerships that align with our scientific mission. We are dedicated to supporting further research into additional diagnostic applications and advanced platforms that will continue to push the boundaries of immunodiagnostics.
Learn about our commitment to quality.